Last reviewed 2026-06-02 · How we verify

Levothyroxine sodium new formulation

Takeda · Phase 2 active Small molecule ✓ Verified May 2026

Levothyroxine sodium new formulation is a Thyroid hormone replacement Small molecule drug developed by Takeda. It is currently in Phase 2 development for Hypothyroidism.

Levothyroxine sodium acts on the thyroid hormone receptor.

A new formulation of Levothyroxine sodium is being studied in clinical trials for its efficacy and safety in healthy individuals and those with hypothyroidism. The new formulation is being compared to the approved formulation, Eutirox, in a randomized, single-dose study.

Likelihood of approval

18.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Takeda is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Levothyroxine sodium new formulation
Sponsor	Takeda
Drug class	Thyroid hormone replacement
Target	Thyroid hormone receptor
Modality	Small molecule
Therapeutic area	Endocrinology
Phase	Phase 2

Mechanism of action

Levothyroxine sodium is a synthetic form of the thyroid hormone thyroxine, which plays a crucial role in regulating metabolism, growth, and development. It works by binding to thyroid hormone receptors in the body, stimulating the production of thyroid hormones and regulating their levels.

Approved indications

Hypothyroidism

Common side effects

Nausea
Headache
Fatigue

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Levothyroxine sodium new formulation CI brief — competitive landscape report
Levothyroxine sodium new formulation updates RSS · CI watch RSS
Takeda portfolio CI

Frequently asked questions about Levothyroxine sodium new formulation

What is Levothyroxine sodium new formulation?

Levothyroxine sodium new formulation is a Thyroid hormone replacement drug developed by Takeda, indicated for Hypothyroidism.

How does Levothyroxine sodium new formulation work?

Levothyroxine sodium acts on the thyroid hormone receptor.

What is Levothyroxine sodium new formulation used for?

Levothyroxine sodium new formulation is indicated for Hypothyroidism.

Who makes Levothyroxine sodium new formulation?

Levothyroxine sodium new formulation is developed by Takeda (see full Takeda pipeline at /company/takeda).

What drug class is Levothyroxine sodium new formulation in?

Levothyroxine sodium new formulation belongs to the Thyroid hormone replacement class. See all Thyroid hormone replacement drugs at /class/thyroid-hormone-replacement.

What development phase is Levothyroxine sodium new formulation in?

Levothyroxine sodium new formulation is in Phase 2.

What are the side effects of Levothyroxine sodium new formulation?

Common side effects of Levothyroxine sodium new formulation include Nausea, Headache, Fatigue.

What does Levothyroxine sodium new formulation target?

Levothyroxine sodium new formulation targets Thyroid hormone receptor and is a Thyroid hormone replacement.

Drug class: All Thyroid hormone replacement drugs
Target: All drugs targeting Thyroid hormone receptor
Manufacturer: Takeda — full pipeline
Therapeutic area: All drugs in Endocrinology
Indication: Drugs for Hypothyroidism

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing